EAvid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	799M 710M 663M 604M 1.14B 76.8B 1.15B 8.02B 3.11B 39.26B 3B 2.93B 126B	P/E 2023	2,007x	P/E 2024	-3.42x
Enterprise Value	964M 857M 800M 729M 1.37B 92.69B 1.39B 9.68B 3.75B 47.39B 3.62B 3.54B 152B	EV / Sales 2023	8.58x	EV / Sales 2024	4.64x
Free-Float	98.58%	Yield 2023 *	-	Yield 2024	-

19/05	Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer	CI
12/05	Avid Bioservices, Inc. Appoints Kerri McCullough Wood as Chief Commercial Officer	CI
25/02	Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California	CI
16/01	Avid Bioservices Appoints Rich Mcavoy as Chief Business Officer	CI
11/11	Avid Bioservices Appoints Dave Stewart as Chief Technology and Transformation Officer	CI
16/09/25	Avid Bioservices Announces CEO Changes	CI
07/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Biotechnology Select Industry Index	CI
07/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Global BMI Index	CI
07/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P TMI Index	CI
06/02/25	Avid Bioservices, Inc. Announces Cessation of Board and Committee Members	CI
05/02/25	Funds managed by GHO Capital Partners LLP and Ampersand Management LLC completed the acquisition of Avid Bioservices, Inc. from a group of shareholders.	CI
05/02/25	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from NASDAQ Composite Index	CI
31/01/25	Avid Shareholders Approve Acquisition by GHO, Ampersand	MT

04/12/24	Stephens Downgrades Avid Bioservices to Equalweight, Price Target is $12.50	MT
08/11/24	RBC Capital Downgrades Avid Bioservices to Sector Perform From Outperform, Adjusts PT to $12.50 From $12	MT
08/11/24	RBC Capital Downgrades Avid Bioservices to Sector Perform, Price Target is $12.50	MT
11/09/24	Avid Bioservices Shares Jump as RBC Boosts Price Target After Bookings Beat	MT
10/09/24	RBC Raises Price Target on Avid Bioservices to $12 From $8, Maintains Outperform Rating	MT

11/02/25	Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience	AQ
07/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ
06/02/25	Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger	GL
06/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	GL
06/02/25	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ

Manager	Title	Age	Since
Kenneth Bilenberg CEO	Chief Executive Officer	-	15/09/2025
Richard McAvoy DFI	Director of Finance/CFO	-	01/06/2026
David Stewart CTO	Chief Tech/Sci/R&D Officer	-	01/11/2025

Peregrine Pharmaceuticals Stock Nasdaq

Stocks

US7136613046

Pharmaceuticals

Valuation: Peregrine Pharmaceuticals

Latest news: Peregrine Pharmaceuticals

Analysts' recommendations: Peregrine Pharmaceuticals

Press Releases: Peregrine Pharmaceuticals

News in other languages: Peregrine Pharmaceuticals

Quotes and Performance

Managers and Directors: Peregrine Pharmaceuticals

Biopharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEREGRINE PHARMACEUTICALS	-2.83%	+7.69%	-	-	799M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+36.07%	+117.61%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+35.72%	+64.82%	617B
ABBVIE INC.	+1.11%	-0.58%	+12.36%	+78.27%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.79%	+41.79%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+20.54%	+40.33%	333B
NOVARTIS AG	-1.46%	-2.89%	+10.57%	+26.54%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-6.17%	+8.82%	244B
AMGEN INC.	-1.04%	-2.79%	+35.30%	+54.42%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+28.44%	+97.54%	179B
Average	-0.97%	-3.39%	+26.07%	+58.90%	410.8B
Weighted average by Cap.	-0.60%	-3.33%	+29.07%	+71.15%

	2023	2024
Net sales	149M 133M 124M 113M 213M 14.35B 215M 1.5B 580M 7.34B 560M 548M 23.54B	140M 124M 116M 106M 199M 13.45B 201M 1.4B 544M 6.88B 525M 514M 22.07B
Net income	560K 498K 464K 423K 798K 53.83M 806K 5.62M 2.18M 27.52M 2.1M 2.06M 88.32M	-141M -125M -117M -106M -201M -13.53B -203M -1.41B -547M -6.92B -528M -517M -22.2B
Net Debt	151M 134M 125M 114M 216M 14.54B 218M 1.52B 588M 7.43B 568M 555M 23.85B	165M 147M 137M 125M 236M 15.89B 238M 1.66B 643M 8.12B 621M 607M 26.08B